AbbVie 10-Qquarter ended 2026-09-30

Executive Summary

AbbVie earns revenue selling prescription medicines and aesthetics products for patients and healthcare providers, largely through pharmaceutical wholesalers. Skyrizi and Rinvoq are replacing Humira as its immunology growth engines, while the $10.6B Apogee acquisition extends its investment in inflammatory diseases. Q3 revenue rose 10%, with those two products more than offsetting continued Humira erosion. Earnings improved much faster than sales because prior-year acquisition and impairment charges fell away; investors should distinguish that rebound from underlying growth while assessing the debt-funded pipeline expansion.

What's Happening in the Business

Skyrizi and Rinvoq gained market share in growing markets, supported by expanded treatment options: U.S. approval of Skyrizi subcutaneous induction for adult Crohn’s disease and additional European indications for Rinvoq. Neuroscience provided another growth source through migraine treatments and Vyalev’s Parkinson’s disease uptake, while aesthetics demand remained uneven.

AbbVie acquired clinical-stage Apogee on 9/3/2026, adding late-stage zumilokibart for atopic dermatitis and APG273 for asthma. Preliminary accounting assigned $9.1B to acquired in-process research and development—drug projects that have not yet reached commercialization—so much of the purchase depends on future clinical and commercial success. Separately, AbbVie licensed RemeGen’s investigational cancer therapy RC148 outside China for $650M upfront, with up to $5.0B of additional milestones and royalties.

A January U.S. government agreement combines lower Medicaid prices and expanded patient-affordability offerings with $100B of U.S. R&D and capital investment over a decade, in exchange for three years of tariff and future price-mandate exemptions. Announced North Carolina and Illinois manufacturing investments support that domestic expansion.

Key Financial Highlights

Product-category totals below are calculated from the reported product revenues.

• Immunology drivers: Skyrizi generated $5.78B, +23%, and Rinvoq $2.71B, +24%; together their growth nearly matched the company’s entire revenue increase. Humira fell 31% to $683M as biosimilars took business.
• Portfolio contrasts: Vyalev reached $286M vs $138M, and Qulipta rose 38% to $398M on uptake and demand. Imbruvica fell 26% to $522M on pricing, demand and collaboration-revenue pressure, offsetting oncology growth elsewhere.
• Earnings comparability: Acquired research and milestone expense fell to $216M from $2.68B in Q3; the prior-year quarter also contained $847M of intangible impairments. These are not equivalent to recurring operating improvements.
• Cash generation: 9M OCF was $14.9B, +7.7%, vs net earnings of $8.53B. Earnings included $5.1B of noncash amortization and $4.73B of contingent-consideration valuation expense; actual contingent payments and working-capital timing partly offset cash generation. FCF after capital expenditures was $14.0B.
• Shareholder returns: 9M dividends were $9.23B vs $8.7B; repurchases reported in management’s discussion were $1.1B vs $606M. Shares outstanding were unchanged, so repurchases did not reduce the net share count.

Risk Assessment

• Pipeline execution: Apogee’s substantial unfinished-drug value and RemeGen’s milestone exposure make clinical failures capable of producing write-downs and weakening acquisition returns.
• Debt and contingent obligations: Higher borrowing sits alongside $27.3B of contingent-consideration liabilities; payments depend on sales and development outcomes and compete with dividends and investment for cash.
• Competition and policy: Humira’s biosimilar erosion demonstrates exclusivity risk, while generic challenges to Ubrelvy and Qulipta and possible appeal of the Botox Medicare-negotiation ruling threaten other franchises.
• Litigation: Pending opioid and Biocell implant cases leave legal exposure despite settlements and reduced accruals.

No risk-factor section was found in this 10-Q. A 10-Q does not have to restate the risk factors in the annual report. Full list: FY2025 10-K.

What to Watch

• Skyrizi and Rinvoq: Combined Q3 revenue was $8.48B. Continued share gains and indication expansion should offset Humira erosion; slowing combined growth would weaken the transition.
• Apogee development: Zumilokibart and APG273 must progress toward approvals and commercialization; setbacks or acquired-asset impairments would challenge the purchase rationale.
• Neuroscience breadth: Vyalev and Qulipta are expanding beyond established brands. Sustained uptake would diversify growth; stalled demand would increase dependence on immunology.
• Financing discipline: Debt rose materially while shares stayed flat. Later filings should show whether cash generation supports investment and dividends while reducing borrowing, or whether leverage keeps rising.

Not present in this filing: Part II Item 1A, Risk Factors.